Prism Ideas

With the arrival of British Summer Time (BST) we get extended daylight hours in the evenings, allowing for more natural light for leisure and outdoor activities. Additionally, BST can contribute to improved mental well-being by providing more opportunities to engage in outdoor activities and socializing after work or school. Hopefully with less rain and warmer days ahead, it is only natural to start thinking ahead to summer and what it may bring. I’m guessing that for many of us in the UK pharmaceutical industry, it will be implementing the new ABPI Code of Practice. Now one month into Q2 of 2024, we are still awaiting its arrival. The public consultation on  proposals to change specific clauses in the Code, as well as changes to the Constitution and procedure of the PMCPA, was launched on 13 December 2023 and ran until 29 February 2024. The 2024 ABPI Code is now expected to be published sometime this quarter, Q2 2024, and will come into force three months after its publication date. The new Code brings with it a hive of activity as pharma companies and the wider industry get to grips with assessing the changes, understanding the impact of the changes, update procedures, revise training materials and roll out the changes across the organisation, all within a three-month window. So, a busy time ahead, made more challenging as we soon enter the period when most employees are looking for time off during summer. 

Strategic and tactical advantage is now even more important as the industry faces tougher times.   Maintaining the highest standards of medical affairs and compliance delivery across global markets is a strong aspiration and we have shown it is achievable with the right team, achieving efficiencies in time, resource and budget. This is a great differentiator for Prism. We mobilise a heritage in clinical development and medical affairs and apply scientific and strategic excellence to the commercial environment.   Our cross-functional but specialist teams create synergies and facilitate the highest quality of service, whilst maintaining fire-walls, confidentiality and regulatory precision. We combine; ◾ Evidence based external and internal scientific communications ◾ Multinational multilingual compliance services ◾ Ability to review and ‘pre-approve’ outward bound materials and interactions A peer-level experience with our stakeholders supports effective collaborations and provides partnership in delivery with transparency across all a stages of the product lifecycle.   This allows our clients to enhance competitiveness and sustains long-term growth.

Last week Prism was proud to sponsor an award at the inaugural One Nucleus Annual Awards dinner held at the prestigious No.11 Cavendish Square in Mayfair, London. The black-tie event was attended by over 200 members of the biotech community and was sponsored by One Nucleus, a not-for-profit life sciences & healthcare membership organisation headquartered in Cambridge. Clive Deverson, Head of Client Services at Prism, was delighted to present the award for best performing R&D service provider of the year to Abzena, a world-class integrated contract development and manufacturing organisation and contract research organisation that specialises in the early discovery of clinical and commercial biotherapeutic and bioconjugation drugs. #onenucleus #annualawards #biotherapeutic #bioconjugationdrugs Photography courtesy of https://lnkd.in/dewuwnH

How to achieve consistent implementation of an holistic 2-3 year medical affairs vision and strategy The greatest success can only be achieved if your medical affairs vision and strategy is consistently delivered across the lifetime of the plan. Too often a great long-term strategy is enthusiastically created and kicked-off, only to find that after a year, many of your stakeholders are doing their own thing, dramatically diluting the impact of the original vision. The holistic view is difficult to maintain. Sometimes this is due to lack of engagement or understanding at the outset but often the drift from the holistic approach is because of personnel change. New stakeholders may not be as invested from the start or perhaps they don’t get the same level of immersion and training. And of course, we can’t ignore human nature! Many people have short-term personal career goals that supersede or derail the consistent implementation of your medical affairs vision and strategy. Achieving consistent long-term buy-in for a medical affairs vision involves effective communication, collaboration, and alignment with key stakeholders. Here are some of the challenges that Prism address and overcome when we develop and run long-term medical affairs strategies; ◽ Lack of understanding of purpose: all stakeholders must be briefed on the need for, and value of, applying the vision and strategy consistently across the duration of the plan. ◽ Stakeholder buy-in: the vision and strategy must be relevant, credible, and useful for all stakeholders. We need to identify and understand the needs and expectations of key stakeholders at the planning stage and throughout. ◽ Alignment and consensus: the vision and strategy must be aligned across all stakeholders (discovery, medical, commercial). Excellent cross-functional relationships need to be fostered and maintained to ensure a holistic approach and better alignment with overall organizational goals. ◽ “Realistically aspirational”: the vision and strategy will guide future development and evidence generation, and we need to ensure forward-looking aspects are realistic. ◽ Global to local: consistent, concise and compelling regional communication needs should be identified and enthusiastically applied. Regular updates, workshops and training is critical as is the early agreement on what level of global/regional/local variation will be allowed. Are these steps easy? Of course not. This holistic objective has to be approached with energy and empathy. It needs include regular assessments of the effectiveness of the communication and engagement efforts to make necessary adjustments. If this is led by an experienced in-house and agency team, you have the best chance of success.  

✨ Happy International Women's Day! ✨ Today, we celebrate the incredible achievements and contributions of women around the world. We recognise and honour those who have paved the way for progress and let's continue to strive for a world of equality

Some medical communication agencies focus on scientific and educational publications, others specialise in the preparation of regulatory documents, and others deal primarily with promotional materials. Here at Prism, we cover all three aspects of medical communications. Our dedicated medical and scientific personnel generate the full spectrum of scientific communications and clinical development documentation, while our compliance department review and sign-off all type of promotional materials. Having this diverse range of expertise within one company allows us to provide seamless support from early-stage clinical development to commercialisation across the medical communications and compliance spaces. While each business unit can provide standalone deliverables to our client, we also work together to provide complementary skills. Whether this is though our clinical development experts providing advice on scientific communication plans, or our compliance experts guiding our medical writers working on promotional brochures, our holistic approach ensures high-quality delivery across the company. If you'd like to know more about our extensive medical communications support capabilities please get in touch.

Good medical writing plays a crucial role in supporting clinical development. Prism have been closely involved in this area of scientific communications for over 20 years. Some of the key reasons good medical writing plays is so important include: - Facilitating effective communication between different stakeholders in the clinical development process and enhancing collaboration - Streamlining clinical development and regulatory approval through the creation of concise, accurate, and digestible documents such as investigator brochures, CSRs and submission dossiers - Maintaining the scientific accuracy and integrity of the research findings and aids in the transparent reporting of all aspects of the trial and its outcomes - Enabling the ethical dissemination of research findings and supporting the informed consent process by providing comprehensible and unbiased information to study participants - Enhancing the credibility and visibility of the research through the publication of well-written manuscripts, abstracts and posters in peer-reviewed journals and at conferences A company’s reputation relies on how they communicate data and interact with the scientific community, and Prism’s approach to Scientific Communications ensures our clients’ strategic goals and business objectives are met while maintaining the highest scientific standards. Our experience also allows us to maximise the interaction between clinical development teams and medical affairs, to link research and medical education for a consistent flow of knowledge across the product life-cycle.

Grüezi mitenand from sunny Switzerland! Here at Prism we have long recognised the importance of Switzerland to the pharmaceutical industry, with Basel being chosen as the site of our first non UK office back in 2009. Approximately 50,000 people work in the pharma industry here in Switzerland – many of these in Basel – and the country is always looking to attract top talent from around the globe. Together, the pharma and chemical industry make up approximately half of Switzerland’s national exports and 7% of annual GDP. Interpharma, the association of Switzerland's research-based pharmaceutical industry, estimated that pharma added over 60 billion francs of value to the Swiss economy in 2020, not bad for a small country! The sector's contributions extend beyond monetary value and have significantly improved the health and well-being of people worldwide. The Swiss pharma industry comprise both global pharmaceutical giants and multiple small-to-medium sized medtech companies, with many of the latter situated in a network of biotech hubs scattered across the country. Switzerland Innovation oversees many of these, and combines the expertise from industry, public institutions, and academia. At Prism we work with both large and small pharma companies, and are ideally placed at the heart of the Swiss pharma industry for all your clinical development and scientific communication needs.

Merry Christmas and Happy New Year, from all at Prism Ideas ✨ 🎄

Congratulations to our Prism Movember team on their fund raising throughout the month of November: A total of £780 raised which was 156% of the target. 🏆 A return to more conventional facial hair (or lack of) to be resumed...until next year... 🥸 The fundraising page is still open for any final donations at the link below https://lnkd.in/eEjutTgD